ArticleOncology letters2025
Meta-analysis of the association between long non-coding RNA maternally expressed gene 3 polymorphisms and cancer susceptibility.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long non-coding RNA (lncRNA) maternally expressed gene 3 (MEG3) polymorphism is associated with cancer risk, however, the results have been inconsistent. Therefore, the present meta-analysis aimed to explore the associations between MEG3 polymorphisms and cancer risk. Online databases were searched and reviewed up to December 2024 for eligible studies. Odds ratios (ORs) and corresponding 95% CIs were calculated to assess the underlying association with genetic models. Furthermore, heterogeneity tests, sensitivity and accumulative analysis and publication bias assessment were conducted to evaluate the robustness of the results. There were 24 publications comprising 45 independent case-control studies included in the present meta-analysis. The pooled results revealed a markedly increased cancer risk with the A allele of the MEG3 rs7158663 G>A variant [for example, GA + AA vs. GG (OR, 1.34; 95% CI, 1.14-1.56; P<0.01; I
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.